What is Syncromune?
Syncromune is a clinical-stage biopharmaceutical company focused on pioneering an in situ platform therapy designed for metastatic solid tumor cancers. Their lead candidate, SYNC-T, is a personalized therapy that integrates partial tumor oncolysis with a multi-target biologic drug. This innovative approach aims to activate the body's immune system directly within the tumor microenvironment, promoting systemic immune activation and combating immunosuppression to foster immune memory. The company's strategy is to enable T cells to recognize and attack cancer cells throughout the body, with two candidates, SV-101 and SV-102, currently undergoing Phase 1 trials.
How much funding has Syncromune raised?
Syncromune has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2024): $100M, investors not publicly disclosed
What's next for Syncromune?
The substantial enterprise-level investment signifies a critical juncture for Syncromune, likely enabling the advancement of its SYNC-T platform through further clinical development and potentially towards commercialization. This strategic financing is expected to accelerate the progression of its Phase 1 candidates, SV-101 and SV-102, and support the expansion of its research and development pipeline. The company's focus on activating endogenous immune responses and establishing immune memory positions it to address significant unmet needs in oncology, particularly for patients with metastatic solid tumors.
See full Syncromune company page
